FDA is finalizing its post-approval pregnancy safety study guidance seven years after publishing a draft, with some changes from the earlier version. The update is designed to reflect evolving scientific understanding while standardizing how sponsors generate pregnancy-related safety evidence after approval. The guidance pertains to the ongoing post-marketing obligations for capturing and evaluating risks to pregnant people and fetuses, an area that has repeatedly been shaped by emerging data, regulatory precedent, and trial design constraints. For the industry, a finalized FDA document can directly affect study design expectations, timing, and the level of detail regulators will expect in pregnancy safety plans. The announcement also highlights that regulatory timelines can extend for years, but final guidance now provides more concrete direction for sponsors preparing submissions and commitments.